Sjögren's and plasma cell variant Castleman disease: a case report

  • Yvonne A Dei-Adomakoh
  • Leslie Quarcoopome
  • Afua D Abrahams
  • Catherine I Segbefia
  • Dzifa I Dey
Keywords: lymphadenopathy, chemotherapy, Rituximab, Plasma Cell Variant Castleman Disease, Sjögren's syndrome

Abstract

Castleman disease is a rare cause of lymphoid hyperplasia and may result in localized symptoms or an aggressive, multisystem disorder. It can mimic other diseases like lymphoma or tuberculosis. It classically presents as a mediastinal mass that involves the lymphatic tissue primarily but can also affect extra lymphatic sites including the lungs, larynx, parotid glands, pancreas, meninges, and muscles. In HIV and HHV8-negative patients with idiopathic multicentric Castleman disease, pathogenesis may involve autoimmune mechanisms. We highlight and report a case of a 34-year-old Ghanaian female who was successfully diagnosed and managed for Sjögren's as well as plasma cell variant Castleman disease with combination chemotherapy and rituximab followed by eighteen months maintenance therapy with pulse chlorambucil and prednisolone and three monthly rituximab.


Keywords: lymphadenopathy, chemotherapy, Rituximab, Plasma Cell Variant Castleman Disease, Sjögren's syndrome

Published
2018-04-09
Section
Articles

Journal Identifiers


eISSN:
print ISSN: 0016-9560